Draft of USP Chapter <711> Dissolution (PDG harmonized document) Published for Comments

Recommendation
Wednesday, 1 October 2025 13.00 - 17.00 h
In the Pharmacopeial Forum, PF 49(3), a proposal of a revised USP General Chapter <711> Dissolution has been published for comments. The background to the publication is the efforts of international harmonization of monographs and general analytical methods of the European, Japanese, and United States pharmacopeias.
The Pharmacopoeial Discussion Group (PDG)
The Pharmacopoeial Discussion Group (PDG), which was created in 1989, brings together
- the Japanese Pharmacopoeia (JP),
- the European Pharmacopoeia (Ph. Eur.),
- and the United States Pharmacopeia (USP).
The PDG works on pharmacopoeial harmonization of excipient monographs and general chapters.
Revised USP Chapter <711> Dissolution
The now published proposal is based on the version of the USP chapter official since 01 May 2023. It represents the official inquiry stage 2A of Revision 5 to the PDG harmonized document.
According to the briefing notes, the draft includes changes in the following sections:
- "Apparatus, Apparatus 1 (basket apparatus)
- Apparatus 3 (Reciprocating Cylinder)
- Apparatus 4 (Flow-Through Cell)
- Apparatus 4 (Flow-Through Cell), Apparatus Suitability
- Procedure, Apparatus 1 and Apparatus 2, Immediate-Release Dosage Forms
- Procedure, Apparatus 1 and Apparatus 2, Delayed-Release Dosage Forms
- Procedure, Apparatus 3 (reciprocating cylinder), Immediate-Release Dosage Forms, Extended-Release Dosage Forms, and Delayed-Release Dosage Forms
- Procedure, Apparatus 4 (Flow-through Cell), Immediate-Release Dosage Forms, Extended-Release Dosage Forms, and Delayed-Release Dosage Forms
- Interpretation, Immediate-Release Dosage Forms, Acceptance Table 1
- Interpretation, Extended-Release Dosage Forms, Acceptance Table 2
- Interpretation, Delayed-Release Dosage Forms, Acid Stage, Acceptance Table 3, and Buffer Stage, Acceptance Table 4"
The draft of the revised chapter is available on PF Online. The comment period is open from now on until 31 July 2023.
Related GMP News
14.07.2025Inadequate Sampling and Component Testing Highlighted in FDA Warning Letter
14.07.2025EMA publishes new Product-Specific Bioequivalence Guidance
14.07.2025Revision of USP Chapter <1039> Chemometrics Published for Comments
14.07.2025Proposal for new USP Chapter <318> NMR Monomer Ratio Determination for Lactide-Glycolide Polymers
14.07.2025New USP Chapter <1221> on Ongoing Procedure Performance Verification (OPPV) Published for Comment
02.07.2025FDA Warning Letter: Missing Testing, No Stability Data, and Inadequate Raw Material Controls